Squarepoint
CUE icon

Squarepoint’s Cue Biopharma CUE Stock Holding History

Squarepoint’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,860
Closed -$61.7K – 4369
2025
Q3 		$61.7K Buy
+2,860
New +$67.1K ﹤0.01% 4197
2025
Q2 		– Sell
-1,159
Closed -$31.7K – 4582
2025
Q1 		$31.7K Buy
1,159
+503
+77% +$18.7K ﹤0.01% 4404
2024
Q4 		$21.5K Buy
+656
New +$24.7K ﹤0.01% 4930
2024
Q3 		– Sell
-1,911
Closed -$71.1K – 4197
2024
Q2 		$71.1K Sell
1,911
-1,961
-51% -$97K ﹤0.01% 3861
2024
Q1 		$220K Buy
3,872
+2,418
+166% +$171K ﹤0.01% 3571
2023
Q4 		$115K Buy
1,454
+824
+131% +$58.9K ﹤0.01% 3730
2023
Q3 		$43.5K Buy
+630
New +$61.5K ﹤0.01% 3650
2023
Q2 		– Sell
-674
Closed -$72.2K – 3636
2023
Q1 		$72.2K Buy
+674
New +$64.3K ﹤0.01% 3021
2021
Q1 		– Sell
-874
Closed -$328K – 3198
2020
Q4 		$328K Buy
874
+209
+31% +$83.5K ﹤0.01% 2137
2020
Q3 		$300K Buy
+665
New +$383K ﹤0.01% 1800

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

Squarepoint's CUE Position: Q4 2025 in Review

Squarepoint sold out of Cue Biopharma (CUE) in Q4 2025, closing a stake of 2,860 shares — an estimated $61.7K sold.

Squarepoint first reported a position in CUE in Q3 2020 and held it in 10 quarters. The position peaked at $328K in Q4 2020. 47 funds tracked by Wall St. Rank hold CUE as of Q4 2025.

  • Squarepoint reported no remaining Cue Biopharma position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 2,860 Cue Biopharma shares in Q4 2025, an estimated $61.7K.
  • Squarepoint first reported a position in Cue Biopharma in Q3 2020 and held it in 10 quarters.
  • Squarepoint's Cue Biopharma position peaked at $328K in Q4 2020.
  • 47 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.